AbbVie shares rise with extension of RINVOQ patent protection to 2037

AbbVie shares rose 3.8% after the company announced it secured extended U.S. patent protection for its blockbuster autoimmune drug RINVOQ (upadacitinib) until April 2037, a significant five-year extension beyond previous analyst expectations. This was achieved through settlements with generic manufacturers. The extended exclusivity is critical for AbbVie, as RINVOQ, which generated $3.75 billion in sales in H1 2025, is central to offsetting revenue declines following the patent expiration of its former top-seller, Humira.

Analysis

AbbVie Inc. has materially de-risked its long-term revenue outlook by securing extended U.S. patent protection for its blockbuster autoimmune drug, RINVOQ, until April 2037. This extension, achieved through settlements with all generic challengers, adds approximately five years of market exclusivity beyond the 2032-2033 timeframe previously anticipated by analysts, assuming pediatric exclusivity is granted. The development is critical for AbbVie's strategy to offset revenue erosion from its former top-seller, Humira, whose patent has expired. RINVOQ's strategic importance is highlighted by its rapid growth, with sales increasing over 48% year-over-year to nearly $3.75 billion in the first half of 2025. This extended protection solidifies the durability of a key revenue stream that is central to the company's immunology portfolio, and the market's positive reception, reflected in a 3.8% share price increase to approximately $220, validates the significance of this intellectual property victory.

Key Decisions for Investors

• Investors should revise long-term financial models for AbbVie to incorporate the newly extended RINVOQ patent life to 2037, which significantly enhances revenue and earnings forecasts beyond the previously expected 2032 patent cliff.
• The resolution of this patent litigation reduces a key overhang for the stock, strengthening the bull case for AbbVie's post-Humira growth narrative and potentially justifying a re-rating of its valuation multiple.
• While the news is positive, it is prudent to monitor for any future disclosures regarding the settlement's undisclosed acceleration provisions and to continue tracking RINVOQ's sales performance to ensure it maintains its strong growth trajectory.